The goal of this observational study is to learn about the effects of semaglutide to coronary artery flow in diabetic and non-diabetic patients. The main question it aims to answer is: Does semaglutide enhance coronary artery flow in diabetic and non-diabetic patients? Participants already planned taking semaglutide by an endocrine specialist as their treatment was assessed with CFR before and 3 months after.
Study Type
OBSERVATIONAL
Enrollment
122
Medicana International Istanbul Hospital
Istanbul, Turkey (Türkiye)
Number of patients who had acute coronary syndrome
Semaglutide is known for its beneficial effects on coronary vasculature. If a patient had myocardial infarction, this patient can no longer participate in study because the CFR ultimately changes.
Time frame: From start of the study to 3 months after
Number of patients who can not lose weight
Semaglutide is not only a diabetic drug but is also known for its weight loss properties. If the patient is unable to lose weight, additional information should be obtained as to why the drug is not working for this specific patient and should be removed from the study.
Time frame: From start to 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.